ALLOGENE THERAPEUTICS

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

23 5 2025 05:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

22 5 2025 14:17:55 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

13 5 2025 13:05:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

06 5 2025 05:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 4 2025 07:12:13 提供 Nasdaq GlobeNewswire

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

07 4 2025 05:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

13 3 2025 13:02:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

03 3 2025 05:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in March Investor Conference

26 2 2025 05:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

25 2 2025 13:10:07 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

13 2 2025 13:30:30 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in February Investor Conferences

04 2 2025 05:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer

29 1 2025 05:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

28 1 2025 05:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

16 12 2024 05:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

12 12 2024 05:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in December Investor Conferences

19 11 2024 05:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

18 11 2024 05:30:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

07 11 2024 13:02:00 提供 Nasdaq GlobeNewswire

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

07 11 2024 07:00:00 提供 Nasdaq GlobeNewswire